title: [Experience of palivizumab in prophylaxis of respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia].
abstract: The data on prophylaxis efficacy of the Palivizumab (synagis) against respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia are shown in the article. No side-effects, good tolerance and decrease of the frequency of bronchopulmonary dysplasia relapses and other viral diseases in whole in such children were registered.
authors.forename: G A
authors.initials: GA
authors.lastname: Aliamovskaia
authors.forename: E S
authors.initials: ES
authors.lastname: Keshinian
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000914:Antibodies, Viral / Q000276:immunology*; D000998:Antiviral Agents / Q000008:administration & dosage; D001997:Bronchopulmonary Dysplasia / Q000150:complications*; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000150:complications / Q000517:prevention & control* / Q000821:virology; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D012189:Retrospective Studies
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000914:Antibodies, Viral; D000998:Antiviral Agents; D000069455:Palivizumab